Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

CONCLUSIONS: Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D.
PMID: 29744674 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA Tags: Breast Cancer Res Treat Source Type: research